KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Current Assets (2018 - 2025)

Esperion Therapeutics (ESPR) has disclosed Current Assets for 8 consecutive years, with $462.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Assets rose 36.86% year-over-year to $462.6 million, compared with a TTM value of $462.6 million through Dec 2025, up 36.86%, and an annual FY2025 reading of $462.6 million, up 36.86% over the prior year.
  • Current Assets was $462.6 million for Q4 2025 at Esperion Therapeutics, up from $360.5 million in the prior quarter.
  • Across five years, Current Assets topped out at $462.6 million in Q4 2025 and bottomed at $170.7 million in Q3 2021.
  • Average Current Assets over 5 years is $293.1 million, with a median of $290.8 million recorded in 2022.
  • The sharpest move saw Current Assets decreased 29.71% in 2021, then soared 68.1% in 2024.
  • Year by year, Current Assets stood at $329.0 million in 2021, then fell by 25.01% to $246.7 million in 2022, then decreased by 18.49% to $201.1 million in 2023, then skyrocketed by 68.1% to $338.0 million in 2024, then skyrocketed by 36.86% to $462.6 million in 2025.
  • Business Quant data shows Current Assets for ESPR at $462.6 million in Q4 2025, $360.5 million in Q3 2025, and $342.6 million in Q2 2025.